NCT06572904View on ClinicalTrials.gov

Effect of Intraarticular Injection of Tenoxicam and Hyaluronic Acid Versus Platelet-Rich Plasma and Hyaluronic Acid in Temporomandibular Joint Internal Derangement

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

October 20, 2024

Study Completion Date

November 20, 2024

Conditions
Temporomandibular Joint Internal Derangement
Interventions
DRUG

Tenoxicam Injectable Product

(EPICOTIL® Tenoxicam 20 mg , Manufactured by: EGYPTIAN INTERNATIONAL PHARMACEUTICAL INDUSTRIES COMPANY, ReStore at a temperature not exceeding 30°C.)

DRUG

Hyaluronic Acid 20 MG/1 ML Injection Gel/Jelly

\* (Hyalubrix® hyaluronic acid sodium salt 30 MG/2 ML, manufactured by Fidia SPA,Italy, stored at temperature \> 25 °C)

Trial Locations (1)

35511

Mansoura university, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER